All Posts

On May 1, 2025, Malaysia began enforcing the Medicine Price Labelling Order 2025. Pharmacies, private hospitals, and clinics must display...

Malaysia’s private pharmacy market is largely unregulated, resulting in wide mark-up variations across channels. Data show retail innovator drugs marked up 25–38%, generics 100–140%, private hospitals at a median 51% (19–117%), community pharmacies around 22% (8–71%), and clinics dispensing generics up to 316%. These dynamics, driven by competition, convenience, and patient behavior, carry major implications for pricing and market access strategies.

ASEAN is one of the world’s fastest-growing healthcare markets—but regulatory fragmentation has long slowed device approvals. That’s...

Thailand’s medical device industry is expanding rapidly, with exports reaching US$5B in 2020, ranking 3rd in ASEAN. Over 513 active companies drive the sector, led by SMEs producing single-use and durable devices, while high-tech imports continue to grow. Supported by BOI incentives, medical tourism, and rising R&D, Thailand is evolving from a consumables exporter into a hub for innovation, AI-driven health tech, and biopharma.